Editorial on Special Issue “Advances and Novel Treatment Options in Metastatic Melanoma”

Caré, Alessandra; Bufalo, Donatella Del; Facchiano, Antonio

doi:10.3390/cancers14030707

Cited by 4 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Activation of alternative signalling pathways: Melanoma cells can activate alternative signalling pathways to bypass the inhibition of the primary pathway targeted by the treatment. The MAPK pathway is routinely targeted while treating melanoma, however if Resistance may develop if other mechanisms, such as the PI3K/AKT pathway, are active [33,49].…”

Section: Mek Inhibitorsmentioning

confidence: 99%

Molecular, Genetic Susceptibility and Immunotherapy of Melanoma

Shenoy,

Nag,

Kolathur

et al. 2023

Preprint

View full text Add to dashboard Cite

Skin cancer is a prevalent and heterogenous disease with several subtypes, such as melanoma, basal cell carcinoma, and squamous cell carcinoma. Among them, melanoma is the most aggressive subtype, with a higher propensity to spread compared to most solid tumors. The application of OMICS approaches has revolutionized the field of melanoma research by providing comprehensive insights into the molecular alterations and biological processes underlying melanoma development and progression. This review aims to offer an overview of melanoma biology, covering its transition from primary to malignant melanoma, as well as the key genes and pathways involved in the initiation and progression of this disease. Utilizing online databases, we extensively explored the general expression profile of genes, identified the most frequently altered genes, and gene mutations, and examined genetic alterations responsible for drug resistance. Additionally, we studied the mechanisms responsible for immune checkpoint inhibitors resistance in melanoma.

show abstract

Section: Mek Inhibitorsmentioning

confidence: 99%

Molecular, Genetic Susceptibility and Immunotherapy of Melanoma

Shenoy,

Nag,

Kolathur

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Melanoma treatment depends on the clinical and pathological staging at the time of diagnosis and includes a range of interventions such as surgery, radiation therapy, chemotherapy and combination therapy [ 4 ]. Despite the potential for a complete cure through surgical excision in cases of early-stage localized melanoma, approximately 20% of patients progress to advanced-stage metastatic melanoma because of the highly invasive nature of melanoma, which enables rapid dissemination to distant organs [ 5 , 6 ]. The only chemotherapeutic agent approved by the US Food and Drug Administration for the treatment of inoperable advanced-stage metastatic melanoma is dacarbazine (5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide; DTIC) [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Silencing of Dicer enhances dacarbazine resistance in melanoma cells by inhibiting ADSL expression

Yeh,

Hsu,

et al. 2023

Aging

View full text Add to dashboard Cite

Dacarbazine (DTIC) is the primary first-line treatment for advanced-stage metastatic melanoma; thus, DTIC resistance is poses a major challenge. Therefore, investigating the mechanism underlying DTIC resistance must be investigated. Dicer, a type III cytoplasmic endoribonuclease, plays a pivotal role in the maturation of miRNAs. Aberrant Dicer expression may contribute to tumor progression, clinical aggressiveness, and poor prognosis in various tumors. Dicer inhibition led to a reduction in DTIC sensitivity and an augmentation in stemness in melanoma cells. Clinical analyses indicated a low Dicer expression level as a predictor of poor prognosis factor. Metabolic alterations in tumor cells may interfere with drug response. Adenylosuccinate lyase (ADSL) is a crucial enzyme in the purine metabolism pathway. An imbalance in ADSL may interfere with the therapeutic efficacy of drugs. We discovered that DTIC treatment enhanced ADSL expression and that Dicer silencing significantly reduced ADSL expression in melanoma cells. Furthermore, ADSL overexpression reversed Dicer silencing induced DTIC resistance and cancer stemness. These findings indicate that Dicer-mediated ADSL regulation influences DTIC sensitivity and stemness in melanoma cells.

show abstract

“…Cancers has dedicated multiple other past and ongoing Special Issues to metastatic cancer, including "Targeting Bone Metastasis in Cancers" [67]; "High-Risk Localized and Locally Advanced Prostate Cancer" [68]; "Advances and Novel Treatment Options in Metastatic Melanoma" [69]; "Metastasis and Tumor Cell Migration of Solid Tumors" [70]; "Understanding Molecular Regulation of Cancer Progression and Metastasis" (https://www.mdpi.com/ journal/cancers/special_issues/Molecular_Regulation_Cancer_Progression_Metastasis, accessed on 7 November 2023); "Genomic Landscape of Breast Cancer: From Primary to Metastasis" (https://www.mdpi.com/journal/cancers/special_issues/genomic_breast, accessed on 7 November 2023); "Targeting Cancer Metastasis" (volume II) (https://www. mdpi.com/journal/cancers/special_issues/TCM, accessed on 7 November 2023); and "New Insights into the Molecular Mechanism of Epithelial Plasticity in Cancer" (https: //www.mdpi.com/journal/cancers/special_issues/Mechanism_Epithelial_Plasticity, accessed on 7 November 2023).…”

mentioning

confidence: 99%